143 related articles for article (PubMed ID: 22594905)
21. Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers.
Miyoshi Y; Kim SJ; Akazawa K; Kamigaki S; Ueda S; Yanagisawa T; Inoue T; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2004 Dec; 10(24):8163-9. PubMed ID: 15623590
[TBL] [Abstract][Full Text] [Related]
22. Prostaglandin E2 (PGE2) downregulates interleukin (IL)-1alpha-induced IL-6 production via EP2/EP4 subtypes of PGE2 receptors in human periodontal ligament cells.
Noguchi K; Maeda M; Ruwanpura SM; Ishikawa I
Oral Dis; 2005 May; 11(3):157-62. PubMed ID: 15888106
[TBL] [Abstract][Full Text] [Related]
23. Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration.
Karavitis J; Hix LM; Shi YH; Schultz RF; Khazaie K; Zhang M
PLoS One; 2012; 7(9):e46342. PubMed ID: 23029485
[TBL] [Abstract][Full Text] [Related]
24. Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts.
Yamamoto S; Kurebayashi J; Kurosumi M; Kunisue H; Otsuki T; Tanaka K; Sonoo H
Cancer Chemother Pharmacol; 2001 Oct; 48(4):283-8. PubMed ID: 11710628
[TBL] [Abstract][Full Text] [Related]
25. The role of interleukin 1 in growth and metastasis of human cancer xenografts.
Elaraj DM; Weinreich DM; Varghese S; Puhlmann M; Hewitt SM; Carroll NM; Feldman ED; Turner EM; Alexander HR
Clin Cancer Res; 2006 Feb; 12(4):1088-96. PubMed ID: 16489061
[TBL] [Abstract][Full Text] [Related]
26. Role of EP2 receptors and cAMP in prostaglandin E2 regulated expression of type I collagen alpha1, lysyl oxidase, and cyclooxygenase-1 genes in human embryo lung fibroblasts.
Choung J; Taylor L; Thomas K; Zhou X; Kagan H; Yang X; Polgar P
J Cell Biochem; 1998 Nov; 71(2):254-63. PubMed ID: 9779823
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
[TBL] [Abstract][Full Text] [Related]
28. Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer.
Basudhar D; Glynn SA; Greer M; Somasundaram V; No JH; Scheiblin DA; Garrido P; Heinz WF; Ryan AE; Weiss JM; Cheng RYS; Ridnour LA; Lockett SJ; McVicar DW; Ambs S; Wink DA
Proc Natl Acad Sci U S A; 2017 Dec; 114(49):13030-13035. PubMed ID: 29087320
[TBL] [Abstract][Full Text] [Related]
29. 15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors.
Fulzele SV; Chatterjee A; Shaik MS; Jackson T; Ichite N; Singh M
Anticancer Drugs; 2007 Jan; 18(1):65-78. PubMed ID: 17159504
[TBL] [Abstract][Full Text] [Related]
30. Cyclooxygenase-2, prostaglandin E2, and prostanoid receptor EP2 in fluid flow shear stress-mediated injury in the solitary kidney.
Srivastava T; Alon US; Cudmore PA; Tarakji B; Kats A; Garola RE; Duncan RS; McCarthy ET; Sharma R; Johnson ML; Bonewald LF; El-Meanawy A; Savin VJ; Sharma M
Am J Physiol Renal Physiol; 2014 Dec; 307(12):F1323-33. PubMed ID: 25234310
[TBL] [Abstract][Full Text] [Related]
31. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells.
Robertson FM; Simeone AM; Mazumdar A; Shah AH; McMurray JS; Ghosh S; Cristofanilli M
J Exp Ther Oncol; 2008; 7(4):299-312. PubMed ID: 19227010
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte/macrophage colony-stimulating factor.
Morgan H; Tumber A; Hill PA
Int J Cancer; 2004 May; 109(5):653-60. PubMed ID: 14999770
[TBL] [Abstract][Full Text] [Related]
33. Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS.
Jensen LR; Huuse EM; Bathen TF; Goa PE; Bofin AM; Pedersen TB; Lundgren S; Gribbestad IS
NMR Biomed; 2010 Jan; 23(1):56-65. PubMed ID: 19650073
[TBL] [Abstract][Full Text] [Related]
34. Prostaglandin E2 receptor EP2 mediates the effect of cyclooxygenase 2 on secondary parathyroid hyperplasia in end-stage renal disease.
Zhang Q; Li S; Ye G; Wang M; Ni L; Kan S; Zhang M; Chen J
Nephrol Dial Transplant; 2019 Apr; 34(4):606-617. PubMed ID: 29982796
[TBL] [Abstract][Full Text] [Related]
35. Cyclooxygenase-2-derived prostaglandin E2 is involved in vascular endothelial growth factor production in interleukin-1alpha-stimulated human periodontal ligament cells.
Bando Y; Noguchi K; Kobayashi H; Yoshida N; Ishikawa I; Izumi Y
J Periodontal Res; 2009 Jun; 44(3):395-401. PubMed ID: 19210337
[TBL] [Abstract][Full Text] [Related]
36. Prostaglandin E2 mediates growth arrest in NFS-60 cells by down-regulating interleukin-6 receptor expression.
de Silva KI; Daud AN; Deng J; Jones SB; Gamelli RL; Shankar R
Biochem J; 2003 Feb; 370(Pt 1):315-21. PubMed ID: 12429018
[TBL] [Abstract][Full Text] [Related]
37. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
38. Effect of ulinastatin on growth inhibition, apoptosis of breast carcinoma cells is related to a decrease in signal conduction of JNk-2 and NF-κB.
Wang H; Sun X; Gao F; Zhong B; Zhang YH; Sun Z
J Exp Clin Cancer Res; 2012 Jan; 31(1):2. PubMed ID: 22217202
[TBL] [Abstract][Full Text] [Related]
39. Silymarin suppresses the PGE2 -induced cell migration through inhibition of EP2 activation; G protein-dependent PKA-CREB and G protein-independent Src-STAT3 signal pathways.
Woo SM; Min KJ; Chae IG; Chun KS; Kwon TK
Mol Carcinog; 2015 Mar; 54(3):216-28. PubMed ID: 24127286
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.
Sakai I; Miyake H; Terakawa T; Fujisawa M
Cancer Sci; 2011 Apr; 102(4):769-75. PubMed ID: 21214673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
